Correction to: npj Digital Medicine 10.1038/s41746-022-00613-w, published online 08 June 2022
The original version of the published Article contained an error in the description of the prostate tissue samples in the Methods and Results sections, which stated that “pretreatment biopsy samples” and “pretreatment prostate biopsies” were used in this study. Both instances have been updated to “pretreatment and posttreatment prostate tissue”, and these changes are reflected in the HTML and PDF versions of the Article. Furthermore, we have added descriptions of the use of posttreatment prostate tissue during model development throughout the Article.
In the interest of transparency and clinical relevance, we repeated the evaluation of model performance in the validation set after removing any cases with post-treatment prostate tissue. This results in a slightly smaller cohort (n = 931) for validation, compared to the 20% validation set used in the original paper, and still demonstrates similar performance to the MMAI algorithms using only pretreatment tissue for each clinical endpoint. Table 2 has been added to the HTML and PDF versions of the Article.
Table 2.
Clinical outcome | NCCN AUC estimates (95% CI) | MMAI AUC (95% CI) | Differential AUC estimate (MMAI - NCCN) |
Comparative test p value |
---|---|---|---|---|
Distant metastasis (5-year) | 0.72 (0.67–0.78) | 0.83 (0.78–0.88) | 0.11 | <0.001 |
Distant metastasis (10-year) | 0.69 (0.64–0.74) | 0.78 (0.73–0.84) | 0.09 | <0.001 |
Biochemical failure (5-year) | 0.61 (0.57–0.64) | 0.69 (0.65–0.73) | 0.08 | <0.001 |
Biochemical failure (10-year) | 0.62 (0.58–0.66) | 0.68 (0.63–0.72) | 0.06 | 0.004 |
Prostate cancer-specific survival (10-year) | 0.67 (0.61–0.73) | 0.77 (0.70–0.83) | 0.10 | <0.001 |
Overall survival (10-year) | 0.57 (0.54–0.61) | 0.65 (0.61–0.69) | 0.08 | <0.001 |
The subcohort represented in this table is smaller than reported in the Article (n = 1109).
AUC area under the curve, CI confidence interval, MMAI multimodal artificial intelligence, NCCN National Comprehensive Cancer Network.
Data availability
The data availability statement has also been updated in the PDF and HTML versions of the Article to read, “The data published in this article will be publicly available six months from publication, through requests made to NRG Oncology at APC@nrgoncology.org”.
Footnotes
These authors contributed equally: Felix Y. Feng, Osama Mohamad.
A list of authors and their affiliations appears online.
Contributor Information
Andre Esteva, Email: aesteva@artera.ai.
NRG Prostate Cancer AI Consortium:
Michael Kucharczyk, Luis Souhami, Leslie Ballas, Christopher A. Peters, Sandy Liu, Alexander G. Balogh, Pamela D. Randolph-Jackson, David L. Schwartz, Michael R. Girvigian, Naoyuki G. Saito, Adam Raben, Rachel A. Rabinovitch, and Khalil Katato
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data availability statement has also been updated in the PDF and HTML versions of the Article to read, “The data published in this article will be publicly available six months from publication, through requests made to NRG Oncology at APC@nrgoncology.org”.